HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

AuthorsGen-Min Lin, Yi-Hwei Li, Lamin E S Jaiteh, Chih-Lu Han
JournalAmerican heart journal (Am Heart J) Vol. 164 Issue 6 Pg. e19; author reply e21 (Dec 2012) ISSN: 1097-6744 [Electronic] United States
PMID23194495 (Publication Type: Letter, Comment)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Complement Membrane Attack Complex
  • Single-Chain Antibodies
Topics
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Complement Membrane Attack Complex (antagonists & inhibitors)
  • Female
  • Humans
  • Male
  • Myocardial Infarction (therapy)
  • Single-Chain Antibodies (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: